ADAR and hepatocellular carcinoma: Some studies demonstrated that the level of ADAR1 in ESCC and the level of ADAR2 in HCC are correlated with patient survival, highlighting the potential of A-to-I editing as a novel biomarker for guiding treatment strategies [169, 171].